Профилактика остеопороза у больных раком предстательной железы при максимальной андрогенной блокаде при применении препарата деносумаб

И. Г. Русаков, Б. Я. Алексеев, S.V. Bystrov · Медицинский вестник Башкортостана · 2011

Androgen-deprivation therapy is well-established in the treatment of prostate cancer (PC). However, it has been associated with bone mineral density (BMD) loss and an increased risk of fracture. Osteoporosis and bone fractures are frequently overlooked complications of androgen deprivation therapy in men with non-metastatic prostate cancer. All such patients should have their BMD monitored and undergo preventive procedures, such as calcium and vitamin D supplementation; patients with low BMD should be offered treatment. The potentials of denosumab and similar medications treatment has shown promising in fracture risk reduction in non-metastatic PC patients.

Cited by 0 works.

Authors